Non-lipidated variants of
The present invention relates to compositions including an isolated non-pyruvylated non-lipidated ORF2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic. The present invention further relates to compositions that elicit a bactericidal immune response in a mammal against an ORF2086 subfamily B polypeptide from serogroup B Neisseria meningitidis , and methods related thereto.
1. An immunogenic composition comprising an immunologically effective amount of a first non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 19, wherein the first non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 19 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
2. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a non-lipidated N. meningitidis , serogroup B, 2086 Subfamily A polypeptide.
3. The immunogenic composition of claim 1 , wherein the Subfamily A Subfamily A polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 55.
4. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 44, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 44 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
5. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 57, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 57 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
6. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 58, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 58 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
7. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 59, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 59 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
8. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 60, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 60 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
9. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 62, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 62 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
10. The immunogenic composition of claim 1 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 64, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 64 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
11. An immunogenic composition comprising an immunologically effective amount of a non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 62, wherein the non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 62 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
12. The immunogenic composition of claim 11 , wherein the non-pyruvylated non-lipidated polypeptide is encoded by a nucleotide sequence comprising SEQ ID NO: 61.
13. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of an immunologically effective amount of a non-lipidated N. meningitidis , serogroup B, 2086 Subfamily A polypeptide.
14. The immunogenic composition of claim 13 , wherein the Subfamily A polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 55.
15. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 44, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 44 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
16. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 57, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 57 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
17. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 58, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 58 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
18. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 59, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 59 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
19. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 60, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 60 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.
20. The immunogenic composition of claim 11 , further comprising an immunologically effective amount of a second non-pyruvylated non-lipidated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 64, wherein the second non-pyruvylated non-lipidated polypeptide lacks cysteine at the N-terminus of SEQ ID NO: 64 and does not exhibit a mass shift of +70 Da compared to the corresponding wild-type non-lipidated polypeptide as measured by mass spectrometry.